UK and Australia deepen life sciences cooperation

UK and Australia deepen life sciences cooperation

Britain and Australia are deepening cooperation across life sciences industries. Joint commitments cover biotechnology, clinical research, regulatory coordination, commercial development, and specialist manufacturing technologies.


The UK and Australia have agreed to strengthen cooperation across life sciences and biotechnology, with plans to expand commercial partnerships, coordinate regulatory activity, and support advanced medicines development.

A bilateral statement published by the UK’s Department for Business, Innovation, Science and Trade sets out commitments involving medicines regulators, research organisations, government trade agencies, and biotechnology industry bodies in both countries.

The agreement covers clinical trials, genomics, precision medicine, medical technology, advanced therapies, digital health, and biotechnology commercialisation.

It follows discussions held in Canberra on 15 September during the second Australia–UK Strategic Innovation Dialogue, established under the innovation provisions of the bilateral Free Trade Agreement.

The 18 November statement brings together existing projects and commitments to further cooperation. It does not establish a single new investment fund or disclose an aggregate value for future commercial agreements.

Both countries intend to strengthen connections between scientific research, regulatory assessment, manufacturing capabilities, and the businesses seeking to develop products for international markets.

Coordinating medicines regulation —

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and Australia’s Therapeutic Goods Administration (TGA) will continue working together on regulatory approaches affecting medicines and medical technologies.

The two agencies already cooperate through bilateral arrangements and international organisations, including the Access Consortium.

That consortium also includes the medicines regulators of Canada, Singapore, and Switzerland, enabling participating authorities to exchange information and coordinate elements of their regulatory assessments.

Collaborative procedures can reduce duplication when developers seek authorisation for medicines across several jurisdictions.

However, cooperation between regulators does not remove the obligation to satisfy the requirements applicable in each market or guarantee that a product will receive approval.

The MHRA and TGA intend to continue sharing experience in developing regulatory approaches for innovative health products.

They have also reaffirmed cooperation on medical device regulation, including continuing implementation of the Australia–UK Mutual Recognition Agreement on conformity assessment.

The arrangements are intended to support the development and commercialisation of new technologies while maintaining existing patient safety and quality requirements.

Connecting research with commercial development —

Austrade and the UK Department for Business, Innovation, Science and Trade will continue promoting bilateral investment, company partnerships, exports, and market access across the life sciences sector.

Clinical research is a particular focus. Australia’s Clinical Trials Initiative promotes the country’s capabilities to international pharmaceutical, biotechnology, and research organisations.

In May 2026, Austrade organised industry seminars at Australia House in London and Milton Park in Oxfordshire, bringing together companies, investors, and research organisations interested in clinical trial opportunities.

The two governments intend to extend this activity through further engagement between commercial and research partners.

Specialist UK research organisations are already involved in joint technology development projects.

The Cell and Gene Therapy Catapult has supported an Australian company developing cell therapy production systems, helping it demonstrate its technology and establish connections within the UK biotechnology industry.

It has also provided health economics and market access analysis for an Australian university research group developing a potential stem cell treatment for heart failure.

These activities support the assessment of technologies at different stages of development, including questions about production methods, prospective clinical applications, and commercial viability.

The Medicines Discovery Catapult is meanwhile collaborating with Australian partners through Innovate UK’s Sustainable Medicines Manufacturing Innovation programme.

One area of work concerns the supply of lead-212, a radioactive isotope being investigated for use in targeted alpha therapies.

Australian technology company entX, through its Isomedica nuclear medicine business, is developing methods to recover useful isotopes from low-level radioactive waste streams.

The cooperation has provided Medicines Discovery Catapult with access to materials supporting research into radiopharmaceuticals and emerging cancer treatments.

Additional discussions concern advanced molecular imaging, including cooperation between Australian research institutions and UK facilities using positron emission tomography.

Such projects can connect specialist scientific facilities, manufacturing technologies, and access to materials required during early treatment development.

Industry cooperation is being supported by AusBiotech and the UK’s BioIndustry Association, which signed a memorandum of understanding in June 2025.

The organisations intend to continue facilitating company introductions, policy engagement, information sharing, and investment connections across the two markets.

The bilateral statement also identifies opportunities to involve additional universities, research institutes, investors, and contract development and manufacturing organisations.

The commitments extend existing cooperation across regulation, clinical research, specialist manufacturing, and commercial development, with individual projects progressing through their respective research, investment, and regulatory arrangements.

—



  • How to mitigate the impact of the memory shortages

    How to mitigate the impact of the memory shortages

    Memory shortages are creating difficult decisions across business technology estates. Chetan Visrolia, business development manager at SHI, outlines practical ways to prioritise workloads, optimise infrastructure, and manage procurement risks.


  • UK and Australia deepen life sciences cooperation

    UK and Australia deepen life sciences cooperation

    Britain and Australia are deepening cooperation across life sciences industries. Joint commitments cover biotechnology, clinical research, regulatory coordination, commercial development, and specialist manufacturing technologies.


  • UK investigates Chinese robotic mower imports

    UK investigates Chinese robotic mower imports

    Britain has opened an investigation into Chinese robotic mower imports. The Trade Remedies Authority will assess allegations of dumping and injury to UK manufacturers before determining whether protective duties are justified.